{
    "2019-03-29": [
        [
            {
                "time": "2018-03-15",
                "original_text": "This Dow stock could be a way to play catch-up to the rally",
                "features": {
                    "keywords": [
                        "Dow",
                        "stock",
                        "catch-up",
                        "rally"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "finance"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-10",
                "original_text": "Wall Street is buzzing about Gilead’s rheumatoid arthritis drug. Here’s why",
                "features": {
                    "keywords": [
                        "Wall Street",
                        "Gilead",
                        "rheumatoid arthritis",
                        "drug"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-05-20",
                "original_text": "Pharma Stock Roundup: AZN Inks Cancer Deal, ABBV, NVS & Others Get Drug Approvals",
                "features": {
                    "keywords": [
                        "Pharma",
                        "AZN",
                        "Cancer Deal",
                        "ABBV",
                        "NVS",
                        "Drug Approvals"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-06-05",
                "original_text": "Jim Cramer Advised His Viewers On Canopy Growth, DowDuPont And More",
                "features": {
                    "keywords": [
                        "Jim Cramer",
                        "Canopy Growth",
                        "DowDuPont"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "finance",
                        "cannabis"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}